ATAI Life Sciences N.V. (ATAI): Price and Financial Metrics

ATAI Life Sciences N.V. (ATAI): $1.34

0.01 (+0.75%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add ATAI to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#125 of 347

in industry

ATAI Price/Volume Stats

Current price $1.34 52-week high $2.85
Prev. close $1.33 52-week low $1.03
Day low $1.30 Volume 1,248,800
Day high $1.44 Avg. volume 1,460,027
50-day MA $1.77 Dividend yield N/A
200-day MA $1.61 Market Cap 224.32M

ATAI Stock Price Chart Interactive Chart >


ATAI Life Sciences N.V. (ATAI) Company Bio


Atai Life Sciences N.V. focuses on operating as a holding company for ATAI Life Sciences AG that operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that are focused on multiple mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a GABA/nicotinic modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01 is a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.


ATAI Latest News Stream


Event/Time News Detail
Loading, please wait...

ATAI Latest Social Stream


Loading social stream, please wait...

View Full ATAI Social Stream

Latest ATAI News From Around the Web

Below are the latest news stories about ATAI LIFE SCIENCES NV that investors may wish to consider to help them evaluate ATAI as an investment opportunity.

GH Research Drags Down Psychedelic Drug Stocks Index By 7%

The 5 constituents in the Psychedelic Drug Stocks Index continue to exhibit extreme volatility week after week.

TalkMarkets.com | November 23, 2023

atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights

Phase 2b study of RL-007 in CIAS patients continues to be on track to report data in 2H 2024 and data from the EMP-01 (MDMA derivative) Phase 1 study is anticipated to report out later this year. Phase 1 data of VLS-01 (a proprietary oral transmucosal film formulation of DMT) demonstrated that 160mg of VLS-01 reached exposure levels comparable to 30mg of IV DMT. Acceptance of three non-clinical poster presentations at upcoming medical meetings, including non-clinical data for RL-007 and two nove

Yahoo | November 14, 2023

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Key Takeaways; Cannabis Sector Trulieve is challenging 280E cannabis taxation, seeking $143 million federal tax refund. TerrAscend raised its full year 2023 guidance, triggering a surge in stock price. Red White & Bloom won the race to acquire Aleafia Health after an earlier stumble. Key Takeaways; Psychedelic Sector Atai strengthened investment in IntelGenx technologies. Awakn’s […]

Yahoo | October 15, 2023

ATAI LIFE SCIENCES ANNOUNCES FILING OF EARLY WARNING REPORT

This press release is being issued pursuant to National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues ("NI 62-103"), in connection with certain transactions completed by atai Life Sciences AG (Nasdaq: ATAI) ("atai") and IntelGenx Technologies Corp. (the "IntelGenx"), that were previously described in a press release issued by IntelGenx on August 31 2023.

Yahoo | October 10, 2023

atai Life Sciences to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit

NEW YORK and BERLIN, Oct. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the Jefferies Inaugural Biotech CNS/Neuro Summit being held from October 11-12, 2023. Details of the company’s participation is as follows: Jefferies Inaugural Biotech CNS/Neuro Summit Format: Fireside Chat Date and Time: Wednesday, October 11th at 8:30 A.M. ET Location: New

Yahoo | October 6, 2023

Read More 'ATAI' Stories Here

ATAI Price Returns

1-mo -16.77%
3-mo -19.28%
6-mo -0.74%
1-year -13.55%
3-year -92.56%
5-year N/A
YTD -4.96%
2023 -46.99%
2022 -65.14%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!